Loading company…
Myricx Bio develops antibody drug conjugates for cancer treatment.
Myricx Bio develops antibody drug conjugates using N-myristoyltransferase inhibitors as payloads, targeting solid tumors and other oncology needs. Founded in 2019 and based in London, UK, it raised GBP 90 million in Series A funding in July 2024, co-led by Novo Holdings and Abingworth. Andrew Bell is the founder.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in